The company has supported a number of approved drugs with its codevelopment strategy including Pfizers Besponsa Eisais Lenvima and Apellis Pharmaceuticals Empaveli. In the latter case Abingworth provided 28 million to help Apellis run a Phase 3 trial of the drug